Citi lowered the firm’s price target on Syndax to $32 from $35 and keeps a Buy rating on the shares. The analyst updated biotechnology models to reflect reported Q4 and 2023 financials.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
Questions or Comments about the article? Write to editor@tipranks.com